The use of angiotensin-converting enzyme inhibitors in renal transplant patients

Transplantation Reviews

Volumn 12, Issue 3, 1998, Pages 148-155

  Paul, Leendert C ^a   Zaltzman, Jeffrey ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001261738     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(98)80021-9     Document Type: Article

References (81)

1. Nath KA, Crumbley AJ, Murray BM, et al: Captopril and renal insufficiency. N EnglJ Med 1983,309:666 (Letter)
2. Skidgel RA, Erdos EG: Biochemistry of angiotensin converting enzyme, in Robertson JIS, NichoIIs MG (eds): The reninangiotensin system. London, Gower Medical Publishing, 1993, plO.l
3. \Vong PC, Hart SD, Zaspel AM, et al: Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: Dup753 (AII-1) and PD 123277 (AII-2).J Pharmacol ExpTher 1990,255:584
4. Harris PJ, Navar LG: Tubular transport responses to angiotensin: editorial re\iew. Am J Physiol 1985,248:F621
5. Raij L, Keane \VF: Glomerular mesangium: its function and relationship to angiotensin II. Am J Med 1985, 79:24 (Suppl 3C)
6. Anderson S, Rennke HG, Brenner BM: Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic h)pertension in the rat. J Clin Invest 1986,77:1993
7. Gansevoort RT, Sluiter \VJ, Hemmelder MH, et al: Antiproteinuric effect of blood pressure-lowering agents: a metaanalysis of comparative trials. Nephrol Dial Transplant 1995, 10:1963
8. \VolfG, Neilson G: Angiotensin II as a renal growth factor. J AmSocNephrol 1993,3:1531
9. Owens EK: Control of h)pertrophic versus growth of vascular smooth muscle cells. Am J Physiol 1989,257:H 1755
10. Jin M, \Vilhelm MJ, Lang RE, et al: Endogenous tissue renin-angiotensin systems from molecular biology- to therapy. AmJ Med 1988,84:28 (Suppl 3A)
11. Milan MA, Carvello P, Izumi S, et al: Novel sites of expression of functional angiotensin II receptors in the late gestation fetus. Science 1989,244:13440
12. Everett AD, Scott J, \ViIfong N, et al: Renin and angiotensinogen expression during the evolution of diabetes mellitus. Hypertension 1992,19:70
13. Gibbons GH, Pratt RE, Dzau VJ: Vascular smooth muscle cell hypertrophy vs hyperplasia: autocrine transforming growth factor- expression determines growth response to Ang II in rat glomerular mesangial cells. J Clin Invest 1992,90:456
14. Kagami S, Border W, Miller D, et al: Angiotensin II stimulates extracellular matrix synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994,93:2431
15. Kaneto II, Morrissey J, Klahr S: Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993,44:313
16. Opelz G, Wujciak T, Ritz E, et al: Association of chronic kidney graft failure with recipient blood pressure. Kidney Int 1998,53:217
17. Raine AEG, Margreiter R, Brunner FP, et al: Report on management of renal failure in Europe, XXII. Nephrol Dial Transplant 1992,2:7 (Suppl 2)
18. Brazy PC, Stead \V\V, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 1989,35:670
19. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N EnglJ Med 1993,329:1456
20. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. lancet 1997,349:1857
21. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 1997,51:2
22. Eddy AA: Molecular insights into renal interstitial fibrosis.J Am See Nephrol 1996, 7:2495
23. Modena FM, Hosteller TU, Salahudeen AK, et al: Progression of kidney disease in chronic renal Iransplant rejection. Transplanlalion 1991,52:239
24. CheighJS, Haschemeyer RH, WangJCL, el al: Hypertension in kidney Iransplanl recipients: effect on long-term renal allograft survival. AmJ H>pertens 1989,2:341
25. Vianello A, Maslrosimone S, Calconi G, et al: The role of hypertension as a damaging factor for kidney grafts under cyclosporine therapy. AmJ Kidney Dis 1993,21:79 (Suppl 2)
26. Luke RG, Curtis JJ, Jones P, et al: Mechanism of post transplant hypertension. AmJ Kidney Dis 1985,5 :A79 (Abstr)
27. Kingma I, Chea R, Davidoff A, et al: Glomerular capillarypressures in long-surviving rat renal allografts. Transplantation 1993,56:53
28. Junaid A, Kren SM, Rosenberg ME, et al: Physiological and structural responses to chronic experimental renal allograft injury. Am JPhysiol 1995,267:F1102
29. Benediktsson H, Chea R, Davidoff A, et al: Antihypertensive drug treatment in chronic renal allograft rejection in the rat: effect on structure and function. Transplantation 1996, 62: 1634
30. Mackenzie US, Tullius SG, Heemann UW, et al: Nephron supply is a major determinant of long-term renal allograft outcome in rats. J Clin Invest 1994,94:2148
31. Heemann UW, Azuma H, Tullius SG, et al: Influence of renal mass on chronic kidney allograft rejection in rats. Transplant Proc 1995,27:549
32. Hosteller TH, OIsonJL, Rennke HG, et al: Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am JPhysiol 1981,241:F85
33. Salahudeen AK, Hosteller TH, Raatz SK, et al: Effects of dietary protein in patients with chronic renal transplant rejection. Kidney Int 1992,41:183
34. Borchhardt K, I laas M, Yilmaz N, et al: Low dose angiotensin converting enzyme inhibition and glomerular permselectivily in renal Iransplant recipients. Kidney Int 1997,52:1622
35. Van der Schaaf MR, Hené RJ, Floor M, et al: Hypertension after renal Iransplantation: calcium channel or converting enzyme blockade? Hypertension 1995,25:77
36. SennesaelJ, LamoteJ, Violel I, el al: Comparison of perindopril and amlodipine in cyclosporine-lreated renal allograft recipients. Hypertension 1995,26:436
37. Neuringer JR, Anderson SA, Brenner BM: The role of systemic and intraglomerular hypertension, in Mitch \VE, Slein JH (eds): The progressive nature of renal disease. New York, Churchill Livingslone, 1992, pi
38. Amuchaslegui SC, Azzollini N, Mister M, et al: Chronic allograft nephropathy in ihe rat is improved by angiotensin II receptor blockade but not by calcium channel anlagonism. J Am Soc Nephrol 1998 (in press)
39. Bochicchio T, Sandoval G, Ron O, et al: Fosinopril prevents hyperfiltralion and decreases proleinuria in posl-lransplanl , hypertensives. Kidney Im 1990,38:873
40. Grekas D, Dioudis C, Kale\Tosoglou I, el al: Managemenl of moderale to severe hypertension and proteinuria by nifedipine retard and perindopril after renal transplantalion. Clin Nephrol 1995,44:299
41. First MR, Vaidya PN, Maryniak RK, et al: Proteinuria following transplantation: correlation \vith hislopalhology and outcome. Transplantalion 1984,38:607
42. Rell K, LindeJ, Morzycka-Michalik M, et al: Effect of enalapril on proteinuria after kidney transplantation. Transplant Int 1993,6:213
43. Traindl O, Falger S, Reading S, et al: The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993,55:1309
44. Barnas U, Schmidt A, Haas M, et al: The effects of prolonged angiotensin-converting enzyme inhibition on excretory kidney function and proteinuria in renal allograft recipients with chronic progressive transplant failure. Nephrol Dial Transplant 1996,11:1822
45. Paredes D, Sola R, Guirado L, et al: Treatment of kidney transplants with chronic rejection using angiotensin-converting enzyme inhibitors. Transplant Proc 1997,29:2587
46. Palmer BF, Dawidson I, Sagalo\vsky A, et al: Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991,52:640
47. Vasquez EM, Pollak R: Effect of calcium channel blockers on graft outcome in cyclosporine-treated renal allograft recipients. Transplantation 1995,60:885
48. Neumayer H-H, Kunzendorf U, Schreiber M: Protective effects of calcium antagonists in human renal transplantation. Kidney Int 1992,41:587 (Suppl36)
49. Ladefoged SD, Andersen CB: Calcium channel blockers in kidney transplantation. Clin Transplant 1994,8:128
50. Curtis JJ, Laskow DA, Jones PA, et al: Captopril-induced fall in glomerular filtration rate in cyclosporin-treated hypertensive patients. J Am Soc Nephrol 1993,3:1570
51. Mourad G, RibsteinJ, Mimran A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993,43:419
52. Pesavento TE, Jones PA, Julian BA, et al: Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J Am Soc Nephrol 1996,7:831
53. \Vickre CG, Norman DJ, Bennison A, et al: Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983, 23:731
54. Gaston RS, Julian BA, Curtis JJ: Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis 1994,24:1
55. Glicklich D, Tellis VA, Matas AJ, et al: No association between posttransplant erythrocytosis, thromboembolic events and cyclosporin therapy. Transplant Proc 1989,21:2141
56. Innés A, Pal CR, Dennis MJ, et al: Post-transplant erythrocytosis and immunosuppression with cyclosporin: a case-control study. Nephrol Dial Transplant 1991,6:588
57. Kessler M, Hestin D, Mayeux D, et al: Factors predisposing to post-transplant erythrocytosis. Clin Nephrol 1996,45:83
58. Dagher FJ, Ramos E, Earsley AJ, et al: Are native kidneys responsible for erythrocytosis in renal allorecipient? Transplantation 1979,26:496
59. Pollak R, Maddux MS, Cohan J, et al: Erythrocythemia following renal transplanation: influence of diuretic therapy. Clin Nephrol 1988,29:119
60. Sun CH, Ward HJ, Paul \VL, et al: Profile of erythropoietin following renal transplantation: a recombinant human erythropoietin-based radioimmunoassay study. N Engl J Med 1989, 321:151
61. Barkis GL, Sauter ER, Hussey JL, et al: The effects of theophylline on erythropoietin production in normal subjects and in patients with er>throcytosis after renal transplantation. N EnglJ Med 1990,323:86
62. Danovitch GM,Jamgotchian NJ, Eggena PU, et al: Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Transplantation 1995,60:132
63. Rostaing L, Demur C, I luyn A, et al: Erythrocytosis after renal transplantation: study of erythroid progenitors and response to enalapril. Transplant Proc 1994,26:280
64. Macdougall 1C, Karim S, Amos R, et al: Polycythemia in renal transplant recipients is not mediated solely by enhanced erythropoietin activity.J Am Soc Nephrol 1992,3:428
65. Islam MS, Bourbigot B, Godet JP, et al: Captopril-induced correction of post renal transplant erythemia. Transpl Int 1990,3:222
66. Klaassen RJL, Van Gelder T, Rischen-Vos J, et al: Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis. Transplantation 1997,64:780
67. Julian BA, Gaston RS, Barker CV, et al: Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis. Kidney Int 1994,46:1397
68. Fyhrquist F, Rosenlof K, Gronhagen-Riska C, et al: Is renin substrate an erythropoietin precursor? Nature 1984,308:649
69. Rasmussen S, Damkjaer MM, Ibsen II, et al: The reninangiotensin system during converting enzjme inliibition with captopril in patients with severe-resistant hypertension. Eur J Clin Invest 1984,14:30
70. Radziwill R, Stuzmann M, Hilgenfeldt U, et al: Converting enzyme inhibitor-induced changes of plasma angiotensinogen concentration in the rat. EurJ Pharmacol 1986,122:59
71. Yeo \VW, Maclean P, Richardson PJ, et al: Cough and enalapril: assessment by spontaneous reporting and \isual analogue scale under double blind conditions. J Hypertens 1994,12:1387
72. Simon SR, Black IIR, Moser M, et al: Cough and ACE inhibitors. Arch Intern Med 1992,152:1698
73. Ferrannini E, Taddei S, Santoro D, et al: Independent stimulation of glucose metabolism and Na+-K+ exchange by insulin in the human forearm. AmJ Physiol 1988,255:E953
74. Swenson ER: Severe hyperkalemia as a complication of timolol: a topically applied beta-adrenergic antagonist. Arch Intern Med 1986, 146:1220
75. Velaquez H, Perazella MA, Wright FS, et al: Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993,119:295
76. Kamel K, Ethier JH, Quaggin S, et al: Studies to determine the basis for hjperkalemia in recipients of a renal transplant who are treated with C) closporin. J Am Soc Nephrol 1992, 2:1279
77. Ducloux D, Sint-Hiller Y, ChalopinJM: Effect of losartan on haemoglobin concentration in renal transplant recipients: a retrospective analysis. Nephrol Dial Transplant 1997, 12:2683
78. I Iricik DE, Broumng PJ, Kopelman R, et al: Captopril induced functional renal insufficiency in patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney. N EnglJ Med 1983,308:373
79. Murphy BF, \\liitworthJA, Kincaid-Smith P: Renal insufficiency with combinations of angiotensin-converting enzyme inhibitors and diuretics. Br Med J 1984,288:844
80. Braunwald E: ACE inhibitors: a cornerstone of the treatment of heart failure. N EnglJ Med 1991,325:351
81. Schweitzer EJ, Matas AJ, Gillingham KJ, et al: Causes of renal allograft loss: progress in the 1980s, challenges for the 1990s. Ann Surg 1991,214:679